Further multivariate survival analysis showed that AURKA expression could be an independent risk factor for PRAD patients (HR = 1.46, 95% CI: 1.08–1.98, p = 0.01), indicating that high expression of AURKA was independently associated with a poorer survival prognosis (Figure 5B). This evidence concerns the gene AURKA and prostate adenocarcinoma.